- Home
- VNO vs LEGN Comparison
VNO vs LEGN Comparison
Compare VNO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- LEGN
- Stock Information
- Founded
- VNO 1946
- LEGN 2014
- Country
- VNO United States
- LEGN United States
- Employees
- VNO N/A
- LEGN N/A
- Industry
- VNO Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- LEGN Health Care
- Exchange
- VNO Nasdaq
- LEGN Nasdaq
- Market Cap
- VNO 7.0B
- LEGN 7.0B
- IPO Year
- VNO N/A
- LEGN 2020
- Fundamental
- Price
- VNO $40.19
- LEGN $32.38
- Analyst Decision
- VNO Hold
- LEGN Strong Buy
- Analyst Count
- VNO 11
- LEGN 13
- Target Price
- VNO $38.00
- LEGN $79.42
- AVG Volume (30 Days)
- VNO 1.3M
- LEGN 1.5M
- Earning Date
- VNO 05-05-2025
- LEGN 05-13-2025
- Dividend Yield
- VNO 1.84%
- LEGN N/A
- EPS Growth
- VNO 248.25
- LEGN N/A
- EPS
- VNO 0.52
- LEGN N/A
- Revenue
- VNO $1,929,890,000.00
- LEGN $627,241,000.00
- Revenue This Year
- VNO N/A
- LEGN $65.96
- Revenue Next Year
- VNO $5.02
- LEGN $52.55
- P/E Ratio
- VNO $74.16
- LEGN N/A
- Revenue Growth
- VNO 2.98
- LEGN 119.97
- 52 Week Low
- VNO $22.42
- LEGN $29.27
- 52 Week High
- VNO $46.63
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- VNO 66.19
- LEGN 45.13
- Support Level
- VNO $38.45
- LEGN $30.25
- Resistance Level
- VNO $39.73
- LEGN $35.81
- Average True Range (ATR)
- VNO 1.25
- LEGN 1.43
- MACD
- VNO 0.61
- LEGN -0.14
- Stochastic Oscillator
- VNO 92.40
- LEGN 38.36
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.